ADVFN - Advanced Financial Network.
HOME» NASDAQ » G » GILD Stock Price » GILD Stock News

Gilead Sciences Share News

 Gilead Sciences (mm) Stock Price
GILD Stock Price
 Gilead Sciences (mm) Stock Chart
GILD Stock Chart
 Gilead Sciences (mm) Stock News
GILD Stock News
 Gilead Sciences (mm) Company Information
GILD Company Information
 Gilead Sciences (mm) Stock Trades
GILD Stock Trades

FDA Approves Truvada to Prevent HIV Infection

WASHINGTON--The U.S. Food and Drug Administration Monday approved a Gilead Sciences Inc. (GILD) HIV drug for use in certain healthy people to help prevent them from contracting the virus that causes AIDS. Truvada was previously approved for use in combination with other drugs to treat HIV. The new approval will allow the drug to be used in people who are considered at high risk of becoming infected with HIV, such as those people have an HIV-infected partner. The FDA said Truvada, a pill taken daily, is to be used in combination with safe-sex practices, such as condom use, to cut the risk of sexually acquired HIV infection in adults. The agency said doctors need to test patients to make sure they are HIV-negative before prescribing Truvada as a prevention tool as well as do follow-up testing every three months. The use of Truvada alone in a person who might become infected with HIV won't treat the virus effectively. "Today's approval marks an important milestone in our fight against HIV," said FDA Commissioner Margaret A. Hamburg in a statement. "Every year, about 50,000 U.S. adults and adolescents are diagnosed with HIV infection, despite the availability of prevention methods and strategies to educate, test, and care for people living with the disease," Dr. Hamburg said.

Stock News for Gilead Sciences (GILD)
10/20/201610:07:00Gilead Announces SVR12 Rates From Four Phase 3 Studies of a Once-Daily...
10/20/201610:05:00Gilead Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib...
10/06/201612:30:00Singapore's Temasek Hires Veteran Goldman Banker
10/05/201612:54:17Statement of Changes in Beneficial Ownership (4)
10/04/201618:03:00FDA Warns on Hepatitis C Drugs
10/03/201619:53:39Statement of Changes in Beneficial Ownership (4)
09/27/201616:05:00Gilead Sciences and the World Health Organization Announce Five-Year...
09/26/201616:56:18Statement of Changes in Beneficial Ownership (4)
09/21/201619:05:00Gilead Sciences Halts Test of Bowel Disease Treatment
09/21/201617:00:00Gilead Terminates Phase 2/3 Study of GS-5745 in Patients With...
09/20/201617:09:06Current Report Filing (8-k)
09/19/201616:47:49Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)
09/16/201606:06:02Free Writing Prospectus - Filing Under Securities Act Rules 163/433...
09/15/201622:01:00Gilead Prices $5 Billion of Senior Unsecured Notes
09/15/201608:58:00Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)
09/13/201610:25:57Confidential Treatment Order (ct Order)
09/13/201600:30:00Scientists Honored for Hep C Research
09/12/201611:18:49Confidential Treatment Order (ct Order)
09/08/201613:36:30Statement of Changes in Beneficial Ownership (4)
09/06/201614:41:06Statement of Changes in Beneficial Ownership (4)

Gilead Sciences and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations